The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
Prior to joining Cipla, Gambhir built a strong track record across the pharmaceutical and healthcare sectors.
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Partnership strengthens healthcare technology distribution capabilities, enabling wider reach of Make-in-India medical devices through government and institutional healthcare networks
Acquisition of Mumbai-based pharmaceutical, nutraceutical and cosmeceutical company expected to be completed by July 2026
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
The new facility will produce precision extruded medical tubing used in minimally invasive medical devices
Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
Subscribe To Our Newsletter & Stay Updated
